← Back to Patent Explorer
US5411940A Expired / Lapsed US ⏱️ 0.0 years remaining

Use of TGF-β3 to reduce the formation of scar tissue in response to corneal trauma

Assignee: Alcon Research LLC
•
Filing: 1993-09-29
•
Granted: 1995-05-02
•
Expires: 2013-09-29
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract The use of TGF-β 3 to reduce the formation of scar tissue as a result of trauma to the cornea of the eye is described. The invention is particularly directed to the use of TGF-β 3 to reduce the formation of scar tissue in connection with ophthalmic surgical procedures involving the cornea, such as laser irradiation of the cornea. A composition containing TGF-β 3 is applied to the site of the trauma to alter the production and composition of extracellular matrix synthesized by fibroblasts, and thereby reduce the formation of scar tissue and consequent impairment of vision.

Inventors

  • 👤 Jon C. Nixon
  • 👤 Billie M. York

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-26 07:14
CPC Classifications
A; A61; A61K; A61K38/00; A61K38/16; A61K38/17; A61K38/18; A61K38/1841

Claims Analysis

Total Claims: 8
Claim 1
Independent Claim 43 words
A method of reducing the formation of scar tissue following trauma to the cornea, which comprises applying to the cornea at the site of the trauma a composition comprising: 0.001 to 10.000 ng/ml of TGF-β 3 ; and a pharmaceutically acceptable vehicle therefor.
Claim 2
Independent Claim 43 words
A method of reducing the formation of scar tissue following trauma to the cornea, which comprises applying to the cornea at the site of the trauma a composition comprising: 0.001 to 10.000 ng/ml of TGF-β 3 ; and a pharmaceutically acceptable vehicle therefor.
Claim 3
Dependent Claim 32 words
A method according to claim 1, wherein the trauma resulted from an ophthalmic surgical procedure, and the composition is topically applied to the site of the trauma in conjunction with said procedure.
Claim 4
Dependent Claim 15 words
A method according to the claim 2, wherein the surgical procedure comprises a refractive surgery.
Claim 5
Dependent Claim 16 words
A method according to claim 3, wherein the refractive surgery comprises laser irradiation of the cornea.
Claim 6
Dependent Claim 21 words
A method according to claim 4, wherein the refractive surgery comprises irradiation of at least a portion of the corneal epithelium.
Claim 7
Dependent Claim 22 words
A method according to claim 4, wherein the refractive surgery comprises debridement of the corneal epithelium, followed by irradiation of the stroma.
Claim 8
Dependent Claim 13 words
A method according to claim 1, wherein the TGF-β 3 is human derived.

References Cited (Backward Citations)

US4981841A Cited
US4983580A Cited
US4962091A Cited
US4717717A Cited
US5057494A Cited
US5124392A Cited
US5061786A Cited
US5108989A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1998-05-01 1998-10-31 1999-05-02 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 2002-05-01 2002-10-31 2003-05-02 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2006-05-01 2006-10-31 2007-05-02 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag